The Electronic Clinical Dementia Rating (eCDR): A Promising Tool for Dementia Screening

By Staff Writer

September 25, 2023

The Electronic Clinical Dementia Rating (eCDR) is a digital tool showing potential in dementia screening and staging, according to a recent cross-sectional study. The eCDR, which can be self-administered remotely and scored automatically, was compared to the Clinical Dementia Rating (CDR), a widely used instrument for detecting and staging dementia due to Alzheimer disease.

Recent study from the USA


The study involved 288 participants, aged 55 years and above, from three Alzheimer Disease Research Centers and the Brain Health Registry. Participants completed both the CDR and eCDR, with the latter being completed remotely and unsupervised.

The findings revealed that the eCDR showed high concordance with the CDR at item, box, and global levels. The concordance ranged from 80% for memory to 99% for personal care. The global score concordance rate was 81%. The study also found that eCDR scores correlated with CDR-SB scores with moderate to high accuracy.

These results suggest that the eCDR is a valid tool for screening and assessing cognitive and functional decline related to Alzheimer disease in older adults. The study emphasises the need for further validation and optimization of eCDR content and scoring in diverse populations and remote settings.

How does this work?

The eCDR works by allowing participants to complete the dementia screening and staging process remotely, using their own device. It is designed to be user-friendly and can be self-administered without supervision. Once the participant completes the eCDR, the tool automatically scores the results. This digital tool is structured similarly to the CDR, rating cognitive and functional impairment across multiple domains. However, unlike the CDR, the eCDR does not rely on clinical judgement to assign scores, instead using an automated scoring algorithm. This feature, along with its remote administration capability, makes the eCDR a potentially more efficient and accessible tool for dementia screening and staging. 


This could lessen the burden of in-clinic research visits by using remote administration with automated scoring could revolutionise dementia screening and assessment, facilitating clinical research, clinical trials, and healthcare.



Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.